EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers

Markus Reitmajer iD, Elisabeth Livingstone, Lucie Heinzerling, Kai-Martin Thoms, Frank Meiss iD, Markus V Heppt, Anja Gesierich, Konstantin Drexler, Friedegund Meier, Max Schlaak, Andrea Forschner iD, Lisa Zimmer

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2026

DOI: 10.1111/ddg.15963 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2026. Verfasst von Markus Reitmajer und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Immune Checkpoint Inhibitors, Practice Patterns, Physicians'. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adjuvant immune checkpoint inhibitors (ICI) and targeted therapy (TT) have revolutionized treatment management for patients with melanoma. However, the current German S3 guideline does not differentiate between patients with and without adjuvant therapy in its recommendations for imaging intervals and follow‐up monitoring, leading to variability in clinical practice. This study provides an overview of surveillance practices among skin cancer centers in the German Dermatologic Cooperative Oncology Group (DeCOG).

Methods

A survey was sent to 80 skin cancer centers in Germany, Austria and Switzerland on November 22, 2023. Responses received by March 10, 2024 were analyzed descriptively.

Results

Fifty‐one responses (64%) were received. Forty centers (78%) reported deviations from the guideline. In stage IIB, 34 centers (67%) conduct imaging including CT scans prior to and after adjuvant therapy. Post‐adjuvant therapy, 36 centers (71%) conduct imaging according to the guideline. Over 90% of the centers offer adjuvant ICI therapy if progression occurs on adjuvant TT and vice versa. In stage IV, after relapse while on adjuvant ICI, 32 centers (63%) would offer adjuvant TT.

Conclusions

Surveillance practices differed among participating centers and often do not align with the current guideline. A consensus based consistent approach would benefit both patients and physicians.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsImmune Checkpoint InhibitorsPractice Patterns, Physicians'HumansGermanySwitzerlandChemotherapy, AdjuvantAustriaNeoplasm StagingSurveys and QuestionnairesMolecular Targeted TherapyGuideline Adherence

Stichwörter der Autor:innen

Adjuvant therapyPET/CTfollow‐up careimmune checkpoint inhibitor (ICI)recurrencetargeted therapy (TT)

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany.
  • Department of Dermatology, University Hospital Essen, Essen, Germany.
  • Department of Dermatology and Allergology, University Hospital, LMU Munich, Munich, Germany.
  • University Medical Center Goettingen, Goettingen, Germany.
  • Department of Dermatology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.

ORCID-Profile: Markus Reitmajer, Frank Meiss, Andrea Forschner

Zitieren

APA

Reitmajer, M., Livingstone, E., Heinzerling, L., Thoms, K. M., Meiss, F., Heppt, M. V., Gesierich, A., Drexler, K., Meier, F., Schlaak, M., Forschner, A., & Zimmer, L. (2026). Real‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15963

Vancouver

Reitmajer M, Livingstone E, Heinzerling L, Thoms KM, Meiss F, Heppt MV, et al. Real‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026. doi:10.1111/ddg.15963

BibTeX
@article{Reitmajer2026,
  author = {Reitmajer, Markus and Livingstone, Elisabeth and Heinzerling, Lucie and Thoms, Kai-Martin and Meiss, Frank and Heppt, Markus V and Gesierich, Anja and Drexler, Konstantin and Meier, Friedegund and Schlaak, Max and Forschner, Andrea and Zimmer, Lisa},
  title = {Real‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2026},
  doi = {10.1111/ddg.15963}
}
Kostenlos starten →